The prospective analysis suggests that the approach could help clinicians identify patients at risk of a stroke who could benefit from anticoagulant treatment.
The model aims to uncover stroke patients at high, medium, or low risk of cerebral amyloid angiopathy, which is linked to additional strokes or dementia.
Milwaukee, Wis.-based TAI Diagnostics is developing a PCR-based assay for cell-free DNA as a way to monitor the health of transplanted organs.
The company said that the funds will allow it to take its ReadyPlex rapid blood group genotyping assays into clinical trials and commercialization.
The kit is designed to be used on the same platform as Grifols' other molecular typing platforms and can provide results within four hours of DNA extraction.
The Alabama Genomic Health Initiative aims to recruit participants from every county in the state and provide genomic analysis and interpretation free of charge.
Based on the results, the researchers, based in Toronto, have initiated a clinical study in Ontario, called OCTANE, that involves a number of cancer centers in the province.